These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 11752405

  • 1. A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum.
    Stowers AW, Chen Lh LH, Zhang Y, Kennedy MC, Zou L, Lambert L, Rice TJ, Kaslow DC, Saul A, Long CA, Meade H, Miller LH.
    Proc Natl Acad Sci U S A; 2002 Jan 08; 99(1):339-44. PubMed ID: 11752405
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial.
    Stowers AW, Cioce V, Shimp RL, Lawson M, Hui G, Muratova O, Kaslow DC, Robinson R, Long CA, Miller LH.
    Infect Immun; 2001 Mar 08; 69(3):1536-46. PubMed ID: 11179324
    [Abstract] [Full Text] [Related]

  • 3. Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys.
    Hisaeda H, Saul A, Reece JJ, Kennedy MC, Long CA, Miller LH, Stowers AW.
    J Infect Dis; 2002 Mar 01; 185(5):657-64. PubMed ID: 11865423
    [Abstract] [Full Text] [Related]

  • 4. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
    Singh S, Miura K, Zhou H, Muratova O, Keegan B, Miles A, Martin LB, Saul AJ, Miller LH, Long CA.
    Infect Immun; 2006 Aug 01; 74(8):4573-80. PubMed ID: 16861644
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys.
    Kumar S, Yadava A, Keister DB, Tian JH, Ohl M, Perdue-Greenfield KA, Miller LH, Kaslow DC.
    Mol Med; 1995 Mar 01; 1(3):325-32. PubMed ID: 8529111
    [Abstract] [Full Text] [Related]

  • 6. Immunization of Aotus monkeys with a functional domain of the Plasmodium falciparum variant antigen induces protection against a lethal parasite line.
    Baruch DI, Gamain B, Barnwell JW, Sullivan JS, Stowers A, Galland GG, Miller LH, Collins WE.
    Proc Natl Acad Sci U S A; 2002 Mar 19; 99(6):3860-5. PubMed ID: 11904437
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV, Biswas S, Pillai CR, Saxena RK.
    Vaccine; 2008 Aug 18; 26(35):4526-35. PubMed ID: 18590786
    [Abstract] [Full Text] [Related]

  • 8. Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1.
    Singh S, Kennedy MC, Long CA, Saul AJ, Miller LH, Stowers AW.
    Infect Immun; 2003 Dec 18; 71(12):6766-74. PubMed ID: 14638762
    [Abstract] [Full Text] [Related]

  • 9. Emerging rules for subunit-based, multiantigenic, multistage chemically synthesized vaccines.
    Patarroyo ME, Patarroyo MA.
    Acc Chem Res; 2008 Mar 18; 41(3):377-86. PubMed ID: 18266328
    [Abstract] [Full Text] [Related]

  • 10. Protection of Aotus monkeys after immunization with recombinant antigens of Plasmodium falciparum.
    Enders B, Hundt E, Knapp B.
    Mem Inst Oswaldo Cruz; 1992 Mar 18; 87 Suppl 3():413-22. PubMed ID: 1343721
    [Abstract] [Full Text] [Related]

  • 11. The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites.
    Darko CA, Angov E, Collins WE, Bergmann-Leitner ES, Girouard AS, Hitt SL, McBride JS, Diggs CL, Holder AA, Long CA, Barnwell JW, Lyon JA.
    Infect Immun; 2005 Jan 18; 73(1):287-97. PubMed ID: 15618165
    [Abstract] [Full Text] [Related]

  • 12. High-level production and purification of P30P2MSP1(19), an important vaccine antigen for malaria, expressed in the methylotropic yeast Pichia pastoris.
    Brady CP, Shimp RL, Miles AP, Whitmore M, Stowers AW.
    Protein Expr Purif; 2001 Dec 18; 23(3):468-75. PubMed ID: 11722185
    [Abstract] [Full Text] [Related]

  • 13. Dominance of conserved B-cell epitopes of the Plasmodium falciparum merozoite surface protein, MSP1, in blood-stage infections of naive Aotus monkeys.
    Hui GS, Nikaido C, Hashiro C, Kaslow DC, Collins WE.
    Infect Immun; 1996 May 18; 64(5):1502-9. PubMed ID: 8613353
    [Abstract] [Full Text] [Related]

  • 14. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria.
    Chang SP, Case SE, Gosnell WL, Hashimoto A, Kramer KJ, Tam LQ, Hashiro CQ, Nikaido CM, Gibson HL, Lee-Ng CT, Barr PJ, Yokota BT, Hut GS.
    Infect Immun; 1996 Jan 18; 64(1):253-61. PubMed ID: 8557348
    [Abstract] [Full Text] [Related]

  • 15. Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen.
    Jones TR, Narum DL, Gozalo AS, Aguiar J, Fuhrmann SR, Liang H, Haynes JD, Moch JK, Lucas C, Luu T, Magill AJ, Hoffman SL, Sim BK.
    J Infect Dis; 2001 Jan 15; 183(2):303-312. PubMed ID: 11110648
    [Abstract] [Full Text] [Related]

  • 16. Elongating modified conserved peptides eliminates their immunogenicity and protective efficacy against P. falciparum malaria.
    Espejo F, Bermúdez A, Vanegas M, Rivera Z, Torres E, Salazar LM, Patarroyo ME.
    J Struct Biol; 2005 Jun 15; 150(3):245-58. PubMed ID: 15890273
    [Abstract] [Full Text] [Related]

  • 17. Differential effects of C3d on the immunogenicity of gene gun vaccines encoding Plasmodium falciparum and Plasmodium berghei MSP1(42).
    Weiss R, Gabler M, Jacobs T, Gilberger TW, Thalhamer J, Scheiblhofer S.
    Vaccine; 2010 Jun 17; 28(28):4515-22. PubMed ID: 20438877
    [Abstract] [Full Text] [Related]

  • 18. Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses.
    Lyon JA, Angov E, Fay MP, Sullivan JS, Girourd AS, Robinson SJ, Bergmann-Leitner ES, Duncan EH, Darko CA, Collins WE, Long CA, Barnwell JW.
    PLoS One; 2008 Jul 30; 3(7):e2830. PubMed ID: 18665258
    [Abstract] [Full Text] [Related]

  • 19. Plasmodium falciparum anti-MSP1-19 antibodies induced by MSP1-42 and MSP1-19 based vaccines differed in specificity and parasite growth inhibition in terms of recognition of conserved versus variant epitopes.
    Hui G, Hashimoto C.
    Vaccine; 2007 Jan 15; 25(5):948-56. PubMed ID: 17023096
    [Abstract] [Full Text] [Related]

  • 20. Structure and function of candidate vaccine antigens in Plasmodium falciparum.
    Anders RF, Murray LJ, Thomas LM, Davern KM, Brown GV, Kemp DJ.
    Biochem Soc Symp; 1987 Jan 15; 53():103-14. PubMed ID: 3332761
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.